Lilly is showcasing Prozac at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Lilly's psychiatry products are all legacy/generic — they're NOT at APA to promote Prozac or Symbyax. Their presence is likely about maintaining institutional relationships, their Centessa acquisition (sleep/narcolepsy pipeline), and broader CNS thought leadership. The real conversation is about where Lilly is going, not where they've been.
Ask about: Centessa integration and what it means for their CNS pipeline; narcolepsy/sleep disorder programs; whether they plan to re-enter active psychiatric drug development; what their APA booth presence signals about future strategy. This is a relationship conversation, not a product conversation. Lilly's scale means even a small pilot win could expand broadly.
Limited near-term Med Affairs opportunity on legacy products. However, Lilly's scale and Centessa pipeline create a forward-looking conversation: ePRO+ and VoiceVitals for upcoming sleep disorder trials, and Videra's continuous monitoring platform for whatever CNS programs emerge from the Centessa integration. Plant the seed for a platform partnership.
Set up a follow-up with Lilly's team and Videra Health.
Email Ryan Roberts →